Join the Oncology Voice Network. Join for Free
Aspiring MSL Insight: When to Present on the Interviewing Company's Product

Aspiring MSL Insight: When to Present on the Interviewing Company's Product


Share This Article


Aspiring MSL Insight: When to Present of the Interviewing Company's Product

In our last episode, insightsspoke about having a back-pocket presentation. In this installment, he presents the counter argument to that. There are times when you have to Tin-Cup it.

The MSL presentation is a make-it or break-it variable in you job interview.

Some candidates play it safe on the presentation, and some people Tin-Cup it. Do you remember the movie Tin Cup. Well, at the end, the main character, Roy McAvoy had to decide to lay up or go for the green. And he decided to go for the green.

As you approach your presentation, you have to make a similar decision. If you have a back-pocket presentation, you can certainly present it and that would be like lay-up…not taking any unnecessary risk. Others, Tin-Cup it and go for the green by presenting on that company’s drug. It’s a high risk/high reward scenario. If you hit the perfect shot and land on the green, you’ve positioned yourself to win. But if you fail to hit it perfectly, it could spell disaster.

If you choose to go for the green, and pull it off, you show the company that you are brave and can learn new things quickly. They will probably think, “She knows the data better than we do, how could we not hire her?” But you need to know that data cold because you are going to be speaking to the experts on the drug.

How can you decide to lay up or tin cup it. That’s where you have to rely on a good recruiter, your caddy, who can help you understand if you’re playing with the lead or playing from behind. If you’re playing without a caddy, then you sense that you’re the lead candidate, Michael advises to lay up. Nail that backpocket presentation. But if you sense that you’re the long shot, Tin Cup it, go for the green - go for the win.

Was that helpful? If so, subscribe to the channel and connect with Michael on linkedin. Also, be sure to join our private LINKEDIN group called KBIC JOBS-MEDICAL AFFAIRS. Thanks

Watch on YouTube

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?
OVN Avatar Omer Ben‐Aharon, Racheli Magnezi, Moshe Leshno, and Daniel A. Goldstein

Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?

Press Release
Announcing the Launch of Voices of Oncology: A Landmark Collaboration with Forbes
OVN Avatar OVN Staff

Announcing the Launch of Voices of Oncology: A Landmark Collaboration with Forbes

Press Release
Introducing OncologyVoiceNetwork.com
OVN Avatar OVN Staff

Introducing OncologyVoiceNetwork.com

Article
Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020
OVN Avatar A. Haslam, M.S. Kim, V. Prasad

Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020

Podcast
The Ideal Roadmap for New MSLs
Partner Avatar MSL Talk: Tom Caravela, Sarah Snyder

The Ideal Roadmap for New MSLs

Article
Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring
OVN Avatar B. Gyawali, E. G. E. de Vries, U. Dafni, T. Amaral, J. Barriuso, J. Bogaerts, A. Calles, G. Curigliano, C. Gomez-Roca, B. Kiesewetter, S. Oosting, A. Passaro, G. Pentheroudakis, M. Piccart, F. Roitberg, J. Tabernero, N. Tarazona, D. Trapani, R. Wester, G.

Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring

Explore OVN